CDRI’s new research hub in Lucknow to facilitate innovation in drug discovery & development

Lucknow:  Marking 70 years of its inception, the Central Drug Research Institute (CDRI) in Lucknow launched a new and advanced research facility called Common Research and Technology Development Hub (CRTDH). As per the motive behind its establishment, this centre would be aiding hospitals and pharmaceutical sector entities in conducting clinical tests and trials. Besides, the latest hub would also facilitate MSMEs and academia with an avenue for high-level research.

The representative from CDRI was quoted saying “CRDTH is not only for scientists but for institutions conducting advanced research in the field of drug discovery. CDRI will not only provide infrastructure support like high-end laboratories and equipment but also the expertise of our scientists.”

With the cutting edge research and development projects undertaken by the CSIR-CDRI, the world has been gifted with a wide range of low-cost efficient drugs and medicines. Amongst its innovative contributions to the drug industry, the most prominent names are Centchroman, the first non-steroidal oral contraceptive and Arteether, a lifesaving drug for cerebral malaria.

In addition to being a top-notch organisation for the development and manufacturing of drugs, CDRI has worked on multiple initiatives to upgrade the quality of elementary research and strengthen human resources.

The CRTDH was inaugurated along with the launch of Atal National Colloquium on Healthcare and Innovation. As a part of this flagship program, a number of renowned and eminent personalities will hold sessions and lectures. This program has been planned to honour the erstwhile Prime Minister Atal Vihari Bajpayee’s vision, that considered scientific development, the topmost priority. This event was also marked by the announcement of the coveted CDRI Awards-2021 for Excellence in Drug Research.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction